NanoVector Inc Profile last edited on: 6/22/09
CAGE: 52FZ0
UEI:
Business Identifier: NO Business Identifier is currently available for this company. 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 02
County: Wake
Congr. District: 02
County: Wake
Public Profile
NanoVector Inc is commercializing a patent pending nanoparticle drug delivery system developed at North Carolina State University (NCSU). NanoVector is seeking partnering opportunities to apply our technology to: * Extend the IP of existing drugs coming off of patent * Combine the NanoVector drug delivery technology with small molucule drug development programs to increase efficacy and/or specificity. * The encapsulation and delivery of unmodified oligonucleotides into a cell for gene silencing or into the cell nucleus for gene splicing. Effective targeted delivery of oligonucleotides is a critical technology enabler for RNAi therapeutics
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2009 | 1 | NIH | $200,000 | |
| Project Title: Multifunctional Therapeutics Using Engineered Plant Virus Nanoparticles | ||||
| 2008 | 1 | NSF | $97,049 | |
| Project Title: Cell Targeting Tool | ||||
Key People / Management
Bruce J Oberhardt -- President
Albert Bender
Albert Bender
Company News
There are no news available.
